Biocytogen Announces Grand Opening of Waltham, MA Facility
State-of-the-Art Facility Signifies Growth of Business in North America and Europe August 16, 2023, Waltham, MA & Beijing, China - Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”),…
Read more
The Key Technology Of Biocytogen’s Fully Human Antibody Renmab Platform Has Been Granted A Chinese Patent
Beijing, China, July 11, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced its independently developed key technology of RenMabTM platform has been…
Read more
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
Exclusive License Agreement for an Oncological Target Antibody to Develop Best-In-Class ADC Beijing, China and London, UK, July 5, 2023 - Biocytogen Pharmaceuticals (Beijing) Co.,…
Read more
Biocytogen Opens San Francisco Office to Accelerate Globalization
Beijing, China and San Francisco, CA, May 31, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new…
Read more
Biocytogen Announces RenLite® Licensing Agreement with Janssen
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech,…
Read more
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BEIJING, China, February 27, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co.,…
Read more
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
BEIJING, China, February 21, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims…
Read more
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
BEIJING, China, and Shanghai, China, January 3, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus…
Read more
Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Beijing, China, December 30, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the…
Read more
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
BEIJING, China, December 19, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New…
Read more